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Guanidino compound metabolism in rats subjected to 20% to 90%
nephrectomy. In mammalian kidney, the proximal convoluted tubule
(PCT) is the main site of arginine (Arg) production. Arginine can be used
in the biosynthesis of guanidino compounds (GC). Since uremic rats have
a lower functional mass of PCT, GC synthesis might be modified,
especially that of guanidinoacetic acid (GAA) which occurs in PCT. In
order to study GC metabolism at different steps of uremia, rats were
subjected to either 42% or 80% nephrectomy (NX); the experiment lasted
for three weeks. Results show that: (1) in plasma, the pattern of GC levels
in 42% NX rats was similar to that of controls except for a clear increase
of -guanidinopropionic acid (13-GPA), whereas in 80% NX rats, all GC
levels sharply increased except that of creatine which decreased. (2)
Urinary excretion of GC in control and 42% NX rats is quite similar
except for GAA which strongly decreased, and for homoarginine (HArg)
and argininic acid (ArgA) which increased. In rats with 80% NX, the
principal modification in GC excretion was a four- to five-fold reduction in
GAA output. (3) After induction of renal failure, Arg, creatine and
guanidinosuccinic acid reabsorption remained unchanged, and that of
HArg decreased. For guanidine and methylguanidine the negative renal
balance remained unchanged, and that of y-guanidinobutyric acid, GAA
and cs-keto-b-guanidinovaleric acid became smaller, suggesting a better
reabsorption. In conclusion, uremia strongly modified GC metabolism
involving mainly those synthesized from Arg; both GAA and creatine
synthesis were strongly decreased probably because of the loss of renal
tissue, mainly PCT.
More than one hundred natural guanidino compounds have
been identified in plant and animal tissues [1]. The guanidino
compounds differ considerably in their structure, metabolism,
distribution and metabolic functions [1]. However, their common
characteristic is the presence of a strongly basic guanidinium
radical. Among the different guanidino compounds, we are focus-
ing our attention on those related to arginine such as guanidino-
acetic acid (GAA), guanidinosuccinic acid (GSA), creatine (CT),
creatinine (CTN), homoarginine (HArg), argininic acid (ArgA),
cs-N-acetylarginine (a-N-AA) and other compounds such as gua-
nidine (G) and methylguanidine (MG). Arginine is very important
for metabolism of other guanidino compounds since its transam-
ination, methylation, hydroxylation, acetylation or transfer of its
amidino group to an amino acid or an amine lead to guanidino
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compounds such as -guanidinopropionic acid (f3-GPA), y-gua-
nidinobutyric acid (y-GBA) and a-keto-h-guanidinovaleric acid
(a-keto-b-GVA).
Arginine, a basic amino acid, can be synthesized in the kidney,
released in the bloodstream and become available for the different
metabolic needs of the body [2, 3]. Recently, the sites of arginine
metabolism have been identified along the nephron. Levillain et a!
[4, 5] have reported that, in mammalian kidney, the proximal
convoluted tubule is the main site of arginine synthesis. Its early
part near the glomerulus, namely the Si [61,produces the highest
amounts of arginine. On the other hand, Takeda et al [7—9] have
shown that guanidinoacetic acid synthesis, which requires arginine
and glycine [10], is also localized in the early part of the proximal
convoluted tubule (Si). Furthermore, guanidinoacetic acid is the
precursor of creatine, creatine phosphate and creatinine. It has
also been found that creatinine is the precursor of methylguani-
dine in liver [ii]. Therefore, the contribution of the kidney to
guanidino compound synthesis is considerable and fulfills the
arginine and GAA needs of other organs under normal physio-
logical conditions.
Alteration of the renal function by disease and nephrotoxic
drugs, which destroy the cells of the proximal tubule, or by
experimental surgery (model of 5/6 nephrectomy), might modify
the metabolism of the different guanidino compounds mainly in
the kidney and the liver [12]. Guanidine, methylguanidine and
GSA, are found to be increased in uremia [13—15] and shown to
be potential toxins [16—22].
We decided to investigate the metabolism of guanidino com-
pounds and some physiological functions of the kidney in animals
with induced renal insufficiency. Therefore, concentrations of
guanidino compounds were measured in plasma and in urine of
rats as well as other biochemical parameters varying with the
degree of renal failure. The functional kidney mass was reduced
by ligation of several branches of the renal arteries leading to the
well known 5/6 nephrectomy model. In this study, we induced
nephrectomy (NX) by renal ablation varying from 20% to 90%.
This work permitted us: (1) to collect new data on the plasma
levels and the urinary excretion of 12 guanidino compounds in
both normal and uremic rats; (2) to establish, for each guanidino
compound, correlations between plasma levels or urinary excre-
tion levels and the degree of renal insufficiency; and (3) to
investigate the movements of the guanidino compounds in the
kidney.
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Calculations
Animals
Male Sprague-Dawley rats (Iffa Credo, France) weighing 200 to
220 g were used for this study. Rats were divided at random into
three groups before inducing renal injury by ligating branches of
the renal arteries as proposed in the model of 5/6 ncphrectomy
which induces severe renal damage.
Rats were anesthetized with pentobarbital (Nembutal 6%, 0.1
ml per 100 g body wt, i.p.). In the first group control rats were
sham operated. In the second group, rats were subjected to a
reduction of the functional renal mass, which varied from 30% to
50%, by either ligating branches of the right renal artery (less than
50% NX) or removing the right kidney (50% NX). In the third
group, nephreetomy of the right kidney and ligating branches of
the left renal artery resulted in approximately 70% to 90% NX.
The rats were housed individually for three weeks and had free
access to tap water and standard chow (M25 Extralabo, France).
Before sacrifice, most of the rats were kept in a metabolic cage for
an adaptative period and had free access to tap water and powder
of M25 chow. Three days later, urine was collected during a
period of 24 hours.
Collection of blood and urine samples
The rats were anesthetized with 0.1 ml pentobarbital per 100 g
body wt. Samples of arterial blood were taken from the abdominal
aorta and transferred into lithium heparinized vacutainer tubes
which were maintained at 4°C. Then, the blood samples were
centrifuged at 4,000 g for 20 minutes at 4°C and a fraction of the
plasma was frozen at —50°C until determination of guanidino
compound concentration. In the other fraction, both urea and
creatinine were measured on an Astra 8 Beckman analyzer.
Urines collected during 24 hours before sacrifice were centri-
fuged at 4,000 g for 20 minutes at 4°C and the volume of urine was
measured. Samples of urine were frozen at —50°C until determi-
nation of the guanidino compounds, whereas, in other samples,
osmolality was determined with a freezing-point osmometer
(Fiske, Uxbridge); urea was measured on a Technieon SMA 6 and
creatinine was determined by a modified Jaffe method.
The remaining kidney(s) were removed and weighed.
Determination of the guanidino compounds
For the guanidino compound (GC) determination, plasma and
urine were deproteinized by mixing equal volumes of a 200 g/liter
triehloroacetic acid solution with the sample. The samples were
centrifuged (8,000 g) in a Beckman mierofuge for five minutes
(Beckman Instruments, Fullerton, CA, USA). Clear supernatant
was diluted with 0.02 N HC1 and used for guanidino compound
analysis in urine; 200 gl supernatant was used for the determina-
tions in plasma.
The concentration of the guanidino compounds was deter-
mined using a Biotronie LC 5001 (Biotronik, Maintal, Germany)
amino acid analyzer adapted for guanidino compound determi-
nation. The guanidino compounds were separated over a cation
exchange column using sodium citrate buffers and were detected
with the fluorescence ninhydrin method as has been reported in
detail earlier [231.
Estimation of the nonfunctional renal mass. The degree of
necrosis was deduced "de visu" during the surgical step by
estimating the importance of the damage following the ligature of
the branches of the renal artery as described earlier [24, 25].
Immediately, there was an isehemia and the corresponding renal
area which was irrigated by the ligated arteriole became darker
than the nonisehemie area. This permitted evaluation of the
fraction of the impaired tissue as compared to the total renal
mass. A value of 50% NX when one kidney was removed was
attributed because, in control rats, the mass of the right kidney did
not differ from that of the left kidney (unpublished data); Kauf-
man et al have observed the same [24].
Calculation of glomerular filtration rate. Although inulin clear-
ance has been recognized to be one of the best methods to
measure the glomerular filtration rate (GFR), in our experimental
protocol, GFR was calculated by using the creatinine clearance
for practical reasons.
Since guanidino compounds were measured in plasma and
urine and since the GFR was known, it was possible to study the
renal balance (B) for each guanidino compound. In order to know
the balance, the amounts of GC which were filtered (entry) and
excreted (exit) per day were calculated by using the following
equation:
B — [(GFR >< [GC]piasma x 1440)] — [Vurine X [GC]urine]
(GFR X [GC]piasnja X 1440)
where [GC] represents the concentration of one guanidino com-
pound in the plasma or urine, V is the volume of urine collected
during 24 hours and 1440 is the time expressed in minutes per day.
This calculation cannot give detailed information on the possible
reabsorption, renal synthesis, concentration in the renal medulla
or excretion along the nephron, but B value indicates the resulting
movement of the guanidino compounds. If the sign of the value is
positive globally it reflects that a GC is reabsorbed, whereas if the
sign is negative, it means that the amount excreted is higher than
the amount filtered.
Statistical analysis
In Tables, the results are presented as mean SE. The data
obtained in the control and experimental group of rats were
compared by the analysis of variance (ANOVA, Statview II SE)
and the Fisher test to determine the P value at the 95% and 99%
levels of significance. For the correlation analysis, the coefficient r
was calculated and the P value was determined from the table of
correlation at the level 95% of significance.
Results
General observations
Results summarized in Table 1 show some biological parame-
ters which have been measured or calculated.
The mean body weight of controls and uremie rats was not
statistically different. In rats with either 42% or 80% NX, in spite
of the renal compensatory growth, the remaining kidney weight
was respectively 9% and 42% lower than the control.
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Table 1. Biological parameters of rats with different percentage of nephrectomy
Experimental groups
1 N 2 N 3 N
Degree of NX % 0 10 41.8 l.7' 21 80.3 l.4C 14
Body weight g 353 6 10 356 6 21 351 8 14
Urine volume ml 14.6 1.0 7 20.1 0.9a 16 32.1 32b,c 9
Uosm mOsmlkg 1120 1637 73 7 1424 42 16 848 89h.c 9
GFR mI/mm 2.05 0.15 7 1.81 0.08 16 0.99 013"" 9
"urea 6.4 0.2 10 8.1 0.3 21 15.9 1.3"," 14
1'c JIM 45 2 10 53 2 21 99 8"" 14
Kidney weight (left + right)
Absolute mg 2498 67 10 2271 55" 21 1440 75k" 14
Relative mg/100 g body wt 709 20 10 657 14" 21 411 20b,c 14
Results are mean SE of (N) rats in groups 1, 2 and 3, respectively. Results were statistically analyzed by ANOVA one Factor, Fisher PLSD.
Abbreviations are: U, urine; P, plasma; Osm, osmolality; GFR, glomerular filtration rate; NX, nephrectomy; Cr, creatinine.
"P < 0.05 and b P < 0.01 vs. control group
P < 0.01 group 3 vs. group 2
Table 2. Plasma guanidino compound levels in control and uremic rats
Experimental groups
1 2 3
Degree of NX % 0 41.8 1.7 80.3 1.4
a-keto-b-guanidinovaleric acid 0.274 0.026 0.376 0.032 0.545 0.05""
Guanidinosuccinic acid 0.063 0.006 0.094 0.008 0.419 0.075""
Creatine 189 15 197 10 114 10b,c
Guanidinoacetic acid 4.59 0.26 4.26 0.20 5.18 0.52"
Argininic acid
/3-guanidinopropionic acid
Creatinine
<0.015
<0.013
44.7 1.9
<0.015
0.061 0.002"
52.9 1.8
0.080 0.008""
0.061 0.006"
98.8 5.6""
y-guanidinobutyric acid 0.296 0.033 0.430 0.037 1.470 0.170""
Arginine 188 11 193 6 184 8
Homoarginine
Guanidine
1.45 0.08
0.237 0.041
1.76 0.09
0.314 0.033
1.59 0.12
0.641 0.082""
Methylguanidine 0.150 0.030 0.173 0.024 0.513 0.068""
Sum GC 429 20 450 10 406 a
Sum GC (creatine omitted) 240 10 253 7 293
Results are mean SE (jrmol/liter) of 10, 21 and 14 rats in groups 1, 2 and 3, respectively. Results were statistically analyzed by ANOVA oneFactor,
Fisher PLSD.
Abbreviations are: NX, nephrectomy; GC, guanidino compounds. The levels of a-N-acetylarginine could not be determined in plasma since an
unknown guanidino compound is eluted very close to a-N-acetylarginine. This unknown peak is not seen in urine.
"P < 0.05 group 3 vs. group 2
b P < 0.01 vs. control
"P < 0.01 group 3 vs. group 2
Urine volume was increased by 38% in rats with 42% NX and
osmolality was decreased by 13%; thus, the amount of osmoles
excreted daily was higher than in the control group (28.3 1.0
mOsm/day vs. 23.7 1.3 mOsm/day, respectively, P < 0.05). In
rats with 80% NX, the variations were more pronounced: urinary
volume was increased by 120% and the osmolality was decreased
by 48% as compared to the control group. The daily amount of
osmoles excreted was 25.4 1.6 (X 10) and did not differ from
that measured in the other groups.
A weak increase of uremia and creatininemia was observed in
rats with 42% NX, whereas they were sharply increased in rats
with 80% NX ("'"2-fold higher).
From these data, GFR was calculated by the clearance of
creatinine. Variations of GFR were very low in rats with 42% NX
and did not differ statistically from the controls. In rats with 80%
NX, GFR was reduced by 51% since more glomeruli were
nonfunctional.
Pattern of guanidino compounds in plasma
Results presented in Table 2 show the pattern and the concen-
tration of guanidino compounds in plasma in both control and
uremic rats. Three weeks after the surgery, the total GC concen-
tration measured in control rats did not differ from that in rats
with 42% NX. In rats with about 5/6 nephrectomy (""80% NX)
the total concentration of guanidino compounds was lower when
compared to the levels in rats with 42% NX. This is explained by
the sharp decrease in creatinemia of rats with severe renal damage
(group 3). Omission of creatine in this calculation indicates that,
in rats of group 3, plasma concentration of guanidino compounds
was significantly increased as compared to that of groups 2 and 1.
The results clearly prove that the increase of guanidino com-
pounds in plasma is not proportional to the degree of renal
damage since the elevation of GC concentration is several-fold
higher in rats with 80% NX than in rats with 42% NX.
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In rats with 42% NX (Table 2), the concentration of /3-guanidi-
nopropionic acid (which was undetectable in control rats and at
the same final level in rats of groups 2 and 3) was significantly
increased (P < 0.01).
In rats with severe renal damage (80% NX), the concentration
of most of the guanidino compounds was several-fold higher than
in groups 1 and 2. Figure 1 A to E indicates that the concentration
of a-keto-5-GVA, y-GBA, G, MG and GSA was exponentially
increased. In parallel, the same exponential increase in urea and
creatinine were observed in the plasma of rats with 80% nephrec-
tomy (not shown). Creatine is the only compound which was
decreased by 40 to 50% as compared to the other groups (P <
0.01; Fig. iF).
The plasma arginine and homoarginine levels were not modi-
fied in rats with nephrectomy.
Pattern of guanidino compounds in urine
A detailed analysis of the guanidino compounds excreted in
urine of control rats shows that creatinine was quantitatively
excreted the most, whereas the excretion of GAA and creatine
was about seven- to ninefold lower. The other guanidino com-
pounds (y-GBA, Arg, G and MG) were excreted in low amounts
whereas traces of a-N-AA, ArgA and HArg were found in urine.
The mean amount of each GC excreted in urine during 24 hours
is given in Table 3. In rats with 42% NX, urinary excretion of most
of the guanidino compounds remained statistically unchanged.
However, urinary excretion of GAA was 32% lower as compared
to the controls (Table 3). In contrast, urinary excretion of ArgA
and I-IArg were significantly increased by 23% and 52%, respec-
tively, as compared to the controls.
In rats with 80% NX, excretion of a-keto--GVA, CT, GAA,
cs-N-AA, and Arg was significantly decreased, whereas the
amounts of GSA, HArg, G and MG excreted per day were
increased in a statistically significant manner as compared to
groups 1 and 2 (Table 3 and Fig. 2). In contrast, excretion of
y-GBA and ArgA were not modified. Excretion of GAA, a good
marker of renal injury, was five-fold lower than in controls; in the
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Fig. 1. Guanidino compound (GC) plasma
concentration as a function of the percentage of
nephrectomy (NX). Results are expressed in
i.tmol/liter N = 45 rats subdivided in 10
controls, 21 and 14 rats with 42% or 80% NX,
respectively. Each open square represents an
individual measurement for a given rat whereas
closed squares and heavy line represent the
mean plasma concentration of a guanidino
compound for a given group of rats (0%, 42%
and 80% NX).
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Table 3. Urinary excretion of guanidino compounds in control and uremic rats
Experimental groups
1 2 3
Degree of NX % 0 41.8 1.7 80.3 1.4
a-keto-6-guanidinovaleric acid
Guanidinosuccinic acid
1.53 0.14
0.138 0.011
1.58 0.10
0.188 0.011
0.94 0.121I
0.372 0037bd
Creatine 14.62 5.12 9.72 2.41 1.11 0.l1
Guanidinoacetic acid 18.40 1.48 12.53 133b 375 103bd
a-N-acetylarginine 0.884 0.296 1.292 0.146 0.655 0.087c
Argininic acid 0.071 0.005 0.092 0.005a 0.077 0.007
y-guanidinobutyric acid 4.42 0.42 4.92 0.20 5.11 0.50
Arginine
Homoarginine
1.12 0.15
0.041 0.007
1.23 0.14
0.086 0009b
0.75 0.09c
0.086 0.013a
Guanidine 1.25 0.10 1.45 0.05 1.51 0.08a
Methylguanidine
Sum GC (without Cr)
1.18 0.17
43.6 6.2
1.31 0.12
34.4 3.6
1.85 011bd
16.2 l.8
Creatinine 127.8 7.5 136.4 6.1 137.6 8.9
Sum GC 171.5 10.4 170.8 8.0 153.8 10.4
Results are mean SE (imol/day) of 7, 16 and 9 rats in groups 1, 2 and 3, respectively. Results were statistically analyzed by ANOVA one Factor,
Fisher PLSD.
Abbreviations are: NX, nephrectomy; GC, guanidino compounds; Cr, creatinine.
ap < 0.05 and bp < 0.01 vs. control
P < 0.05 and dp < 0.01 group 3 vs. group 2
same way, creatine was nearly 13-fold lower than in the controls
(Table 3 and Fig. 2 A, B).
Creatinine was the most excreted guanidino compound in
urine, and the amounts excreted daily were in the same range in
the three groups of rats. When calculating the total amount of GC
excreted per day, except creatinine, the sum of GAA and CT
represented 76%, 65% and 30% of GC in controls, 42% NX and
80% NX rats, respectively. This suggests that the metabolic
pathway of GAA and CT is strongly modified and the more
important the degree of nephrectomy, the lower the synthesis of
both GAA and CT becomes (Table 3).
It is noteworthy that when renal tissue is destroyed (for
example, in uremia), the urinary excretion of those guanidino
compounds that are mainly synthesized in kidney like Arg and
GAA, and consequently their metabolites like CT, decreased. On
the other hand when organs other than the kidneys are involved in
the GC synthesis, urinary excretion of these GC either increased
or remained unchanged (Fig. 2 and Table 3).
Renal balance of guanidino compounds
The daily amounts of GC filtered by the kidney are presented in
Table 4. Briefly, the results show that about 1.2 to 1.3 mmoles of
GC were filtered per day in both controls and rats with 42% NX,
whereas it was divided by two in 80% NX rats. In rats of group 2,
the amounts of each GC filtered per day did not differ from the
controls. In rats with severe renal damage (group 3), a-keto--
GVA, CT, GAA, Arg and HArg were less filtered; in the opposite,
the amounts of GSA, y-GBA, and MG filtered were increased
about 2.6-fold.
Using the equation given in the Methods section, in control rats
GSA, CT, Arg and I-IArg were calculated to be reabsorbed. As
previously demonstrated by Bergeron et al [18, 26], Arg was
totally reabsorbed (99.9%); a similar conclusion can be proposed
for HArg. In contrast to creatinine which was excreted, creatine,
a compound which has a similar chemical structure, was nearly
entirely reabsorbed (98%). About 16% of the filtered GSA was
reabsorbed in controls. After induction of renal failure, Arg, GSA
and CT reabsorption remained unchanged. In contrast, reabsorp-
tion of HArg was proportionally decreased to the degree of renal
failure (Fig. 3D). In nephrectomized rats, no traces of p-GPA
were found in urine in spite of its high plasma concentration. This
suggests that f3-GPA filtered was either totally reabsorbed or
metabolized in the kidney.
Also, the amount of a-keto-6-GVA, GAA, y-GBA, G and MG
excreted in urine of control rats was higher than the amount of
these compounds filtered. After nephrectomy, the negative bal-
ance became smaller for a-keto-b-GVA, GAA, y-GBA (Fig. 3 A,
B, C) and could even become positive. This is illustrated in rats
with 80% nephrectomy where GAA was mainly reabsorbed. The
negative balance for G and MG remained unchanged after
induction of renal failure.
Discussion
In plasma of rats with moderate renal failure (42%), our results
indicate that the concentration of f3-GPA was statistically in-
creased while urinary excretion of GAA, a well known marker of
renal injury, was decreased by 32%. Such an increase in plasma
13-GPA concentration has been reported in uremic patients [271.
The metabolic pathway for the biosynthesis of 13-GPA and its
physiological role remain unclear. Moreover, /3-GPA has been
reported to be a toxic compound [27, 28]. However, although the
increase of /3-GPA is related to the onset of renal failure, it is not
specific. Indeed, in fasted rats an increase of the plasma 13-GPA
levels also has been found [231. Consequently, in rats with low NX,
plasma guanidino compounds cannot be used to detect the onset
of renal failure and GAA remains the best urinary marker.
Most of the data presented in Tables 2, 3 and 4 show that only
a few guanidino compounds had significantly modified levels in
plasma and urine of rats with moderate renal failure, meaning
that only a few metabolic pathways were disturbed. In contrast,
the composition of both plasma and urine of rats with severe renal
damage (80% NX) exhibited important changes, suggesting that
the metabolism of nearly all guanidino compounds was strongly
affected.
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These results indicate that the biosynthesis of GSA is consid-
erably increased in uremic rats. The data are consistent with those
found in uremic patients by Cohen, Stein and Bonas [13]. Perez et
al [12] discovered that the liver of uremic rats enhances its rate of
GSA synthesis. The biochemical basis for the increased biosyn-
thesis of GSA in uremia has been explained by Natelson and
Sherwin [29], who proposed that urea produced in the urea cycle
could be recycled in a "guanidine cycle" in order to form GSA as
an overflow product.
Concerning the metabolic pathway of GAA and CT, it is known
that GAA is synthesized by transamidination from arginine to
glycine in the proximal convoluted tubule [30] and is further
converted into creatine (CT) mainly in the liver. In our uremic
rats (80% NX), in spite of the renal hypertrophy of the cortical
zone (which contains proximal convoluted tubules), the amounts
of GAA synthesized were sharply decreased because the urinary
excretion of this compound was reduced five-fold (Table 3). Thus,
it seems that, in uremia, the kidney has a lower capacity to
synthesize GAA than in control rats. Inouchi et al proposed that
the total activity of the renal glycine amidino transferase is lower
in uremic rats than in control rats [31]. In 5/6 nephrectomized rats,
our results and those of Inouchi et al show that both plasma
concentration and urinary excretion of creatine fall dramatically
[31]. The same observation has been reported when the renal
cortex was destroyed by aminosides [32]. Since renal GAA
synthesis decreased, lower amounts of GAA will be available for
the hepatic synthesis of creatine. We propose that the rate limiting
step of hepatic synthesis of CT depends on GAA availability.
Probably to compensate the low GAA synthesis in rats with severe
renal failure, about 55% of the amount of GAA filtered was
reabsorbed (Fig. 3). In contrast, in control rats about 45% of the
amount of GAA filtered was excreted (Fig. 3).
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Fig. 2. Urinaty ercretion of guanidino
compounds (GC) as a function of the percentage
of nephrectomy (NX). For each rat, urine was
collected during 24 hours and results are
expressed in tmol GC excreted per day. N =
32 rats including 7 controls, 16 and 9 rats with
42% or 80% NX, respectively. Each closed
square represents an individual measurement
for a given rat. Heavy lines are lines of
regression and "r" is the coefficient
of correlation; in each case, P < 0.01.
Abbreviations are: GAA, guanidinoacetic
acid; CT, creatine; G, guanidine; MG,
methylguanidine; GSA, guanidinosuccinic acid.
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Table 4. Amounts of guanidino compounds filtered per day
Experimental groups
1 2 3
Degree of NX % 0 41.8 1.7 80.3 1.4
a-keto-b-guanidinovaleric acid
Guanidinosuccinic acid
0.745 0.059
0.172 0.020
0.894 0.058
0.206 0.010
0.655 0.072c
0.540 0.083w
Creatine 567 46 535 33 158 27"
Guanidinoacetic acid 13.15 1.39 11.31 0.97 8.37 1.86a
Argininic acid 0.055 0.012 0.064 0.015 0.074 0.009
f3-guanidinopropionic acid
y-guanidinobutyric acid
Arginine
Homoarginine
NA
0.775 0.127
550 51
4.26 0.43
0.120 0.016
1.118 0.105
481 27
4.91 0.40
0.077 0.021
2.190237 3l
2.07 0.33w'
Guanidine 0.502 0.112 0.643 0.050 0.687 0.061
Methylguanidine
Sum GC (no Cr and CT)
0.285 0.057
571 51
0.327 0.036
501 28
0.532 0.030w
252
Creatinine 127.9 7.6 136.4 6.1 137.8 8.8
Sum GC 1,266 85 1,173 49 549 65
Results are mean SE (.tmol/day) of 7, 16 and 9 rats in groups 1, 2 and 3, respectively. Results were statistically analyzed by ANOVA one Factor,
Fisher PLSD.
Abbreviations are: NX, nephrectomy; GC, guanidino compounds; CT, creatine; Cr, creatinine; NA, not applicable.
P < 0.05 and 'P < 0.01 vs. control
p < 0.05 and dp < 0.01 group 3 vs. group 2
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To have a good indicator of the kidney function, we correlated
GAAurinary excretion with the weight of the kidney as suggested
by Cohen and Patel [33]. As depicted in Figure 4, the more
important the renal injury, the lower were GAA and CT synthesis
and excretion per day. This kind of representation could be used
to follow the evolution of renal damages.
Guanidine and methylguanidine are known to be toxic com-
pounds which accumulate in body fluids, mainly in the intracellu-
lar compartment where they exert their deleterious effects [14]. It
has been demonstrated that MG induces a uremic-like syndrome
when injected subcutaneously in dogs [14]. Our results indicate
that G and MG synthesis were increased in uremic rats. Depend-
ing on the authors, results obtained in uremic patients are
conflicting. On the one hand, Menichini and Giovannetti have
reported that serum concentration of guanidine is correlated with
creatininemia but its urinary excretion is not different when
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Inhibition of nitric oxide formation by MG has been recently
confirmed by Hasan et al [37].
We focused on the results concerning the renal balance of the
GC. From the data presented in Tables 3 and 4, and by using
the equation given in the Methods, we obtained a view on the
resulting movement of each GC inside the kidney. In the three
groups of rats, GSA, CT, Arg and HArg were mainly reabsorbed
but not to the same extent. In contrast, the negative balance for
y-GBA, a-keto--GVA and GAA in control rats indicates that the
amount excreted is more important than that filtered (Fig. 3),
suggesting that an additional amount of these GC has been added
to the luminal fluid of the nephron. One or more of the following
hypotheses might be involved: (1) the GC might be concentrated
in the renal inner medulla, as is known for urea and as has been
recently demonstrated for amino acids [38, 39]. (2) Guanidino
compounds might be synthesized in the proximal tubule as known
for Arg and GAA or in the distal tubule. (3) Guanidino com-
pounds might be transported from the blood into the cell and
further secreted into the tubular lumen. Such a secretion has been
reported for strong organic bases in mammalian kidney [40]. In
nephrectomized rats, y-GBA, a-keto--GVA and GAA were
more reabsorbed, but the mechanisms remained unexplained.
In conclusion, destruction of the renal tissue induces important
changes in guanidino compound metabolism in the rat. In rats
with 80% nephrectomy, plasma GC levels are sharply increased
except for creatine. Urinary excretion and renal balance of the
guanidino compounds are disturbed after the induction of renal
failure.
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